Suppr超能文献

预测成人复杂性尿路感染门诊发作时对甲氧苄啶-磺胺甲恶唑、氟喹诺酮、呋喃妥因和第三代头孢菌素不敏感的临床风险评分

Clinical Risk Scores to Predict Nonsusceptibility to Trimethoprim-Sulfamethoxazole, Fluoroquinolone, Nitrofurantoin, and Third-Generation Cephalosporin Among Adult Outpatient Episodes of Complicated Urinary Tract Infection.

作者信息

Lodise Thomas P, Chen Lie Hong, Wei Rong, Im Theresa M, Contreras Richard, Bruxvoort Katia J, Rodriguez Mauricio, Friedrich Larry, Tartof Sara Y

机构信息

Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, New York, USA.

Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.

出版信息

Open Forum Infect Dis. 2023 Jun 14;10(8):ofad319. doi: 10.1093/ofid/ofad319. eCollection 2023 Aug.

Abstract

BACKGROUND

Clinical risk scores were developed to estimate the risk of adult outpatients having a complicated urinary tract infection (cUTI) that was nonsusceptible to trimethoprim-sulfamethoxazole (TMP-SMX), fluoroquinolone, nitrofurantoin, or third-generation cephalosporin (3-GC) based on variables available on clinical presentation.

METHODS

A retrospective cohort study (1 December 2017-31 December 2020) was performed among adult members of Kaiser Permanente Southern California with an outpatient cUTI. Separate risk scores were developed for TMP-SMX, fluoroquinolone, nitrofurantoin, and 3-GC. The models were translated into risk scores to quantify the likelihood of nonsusceptibility based on the presence of final model covariates in a given cUTI outpatient.

RESULTS

A total of 30 450 cUTIs (26 326 patients) met the study criteria. Rates of nonsusceptibility to TMP-SMX, fluoroquinolone, nitrofurantoin, and 3-GC were 37%, 20%, 27%, and 24%, respectively. Receipt of prior antibiotics was the most important predictor across all models. The risk of nonsusceptibility in the TMP-SMX model exceeded 20% in the absence of any risk factors, suggesting that empiric use of TMP-SMX may not be advisable. For fluoroquinolone, nitrofurantoin, and 3-GC, clinical risk scores of 10, 7, and 11 predicted a ≥20% estimated probability of nonsusceptibility in the models that included cumulative number of prior antibiotics at model entry. This finding suggests that caution should be used when considering these agents empirically in patients who have several risk factors present in a given model at presentation.

CONCLUSIONS

We developed high-performing parsimonious risk scores to facilitate empiric treatment selection for adult outpatients with cUTIs in the critical period between infection presentation and availability of susceptibility results.

摘要

背景

临床风险评分旨在根据成人门诊患者临床表现中的可用变量,估计其发生对甲氧苄啶-磺胺甲恶唑(TMP-SMX)、氟喹诺酮、呋喃妥因或第三代头孢菌素(3-GC)不敏感的复杂性尿路感染(cUTI)的风险。

方法

对南加州凯撒医疗集团的成年门诊cUTI患者进行了一项回顾性队列研究(2017年12月1日至2020年12月31日)。分别针对TMP-SMX、氟喹诺酮、呋喃妥因和3-GC制定了风险评分。这些模型被转化为风险评分,以根据特定cUTI门诊患者中最终模型协变量的存在情况来量化不敏感的可能性。

结果

共有30450例cUTI(26326例患者)符合研究标准。对TMP-SMX、氟喹诺酮、呋喃妥因和3-GC不敏感的发生率分别为37%、20%、27%和24%。在所有模型中,既往使用过抗生素是最重要的预测因素。在没有任何风险因素的情况下,TMP-SMX模型中不敏感的风险超过20%,这表明经验性使用TMP-SMX可能不可取。对于氟喹诺酮、呋喃妥因和3-GC,在纳入模型时既往抗生素累积数量的模型中,临床风险评分分别为10、7和11时预测不敏感的估计概率≥20%。这一发现表明,对于在就诊时给定模型中存在多个风险因素的患者,在经验性考虑使用这些药物时应谨慎。

结论

我们开发了高效简约的风险评分,以便在感染出现至药敏结果可用的关键时期,为成年门诊cUTI患者的经验性治疗选择提供便利。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e84d/10390854/c1777924aad3/ofad319f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验